William E. Duke Jr. Net Worth

Mr. William E. Duke Jr. biography

William E. Duke Jr. is the Chief Financial Officer at Kaleido Biosciences Inc.

What is the salary of Mr Jr?

As the Chief Financial Officer of Kaleido Biosciences Inc, the total compensation of Mr Jr at Kaleido Biosciences Inc is $672,869. There are 2 executives at Kaleido Biosciences Inc getting paid more, with Jerald Korn having the highest compensation of $1,505,420.

How old is Mr Jr?

Mr Jr is 49, he's been the Chief Financial Officer of Kaleido Biosciences Inc since . There are 12 older and 5 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.

What's Mr Jr's mailing address?

William's mailing address filed with the SEC is C/O KALEIDO BIOSCIENCES,INC, 65 HAYDEN AVE, LEXINGTON, MA, 02421.

Insiders trading at Kaleido Biosciences Inc

Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm и Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.

What does Kaleido Biosciences Inc do?

the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.

Kaleido Biosciences Inc executives and stock owners

Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:

• Jerald Korn,
  General Counsel, Corporate Secretary
• Katharine Knobil,
  Chief Medical Officer and Head of Research and Development
• William E. Duke Jr.,
  Chief Financial Officer
• Daniel L. Menichella B.A., M.B.A.,
  Pres, CEO & Director
• Jean Mixer,
  Independent Director
• Theo Melas-Kyriazi,
  Independent Director
• Michael Bonney,
  Chairman of the Board
• Anthony Quinn,
  Independent Director
• Grady Burnett,
  Independent Director
• Bonnie Bassler,
  Independent Director
• Anne Prener,
  Independent Director
• William Duke,
  Chief Financial Officer
• Daniel Menichella,
  President, Chief Executive Officer, Principal Executive Officer
• Dr. Alison Long M.D., Ph.D.,
  Chief Medical Officer
• Dr. Mark A. Wingertzahn Ph.D.,
  Sr. VP of R&D and Head of Devel.
• Susan Stewart J.D.,
  Chief Regulatory Affairs – Advisor
• Dr. Johan Van Hylckama Vlieg Ph.D.,
  Chief Scientific Officer
• Kimberly Hocknell,
  Sr. VP of Technical Operations
• Jerald Korn J.D.,
  COO, Gen. Counsel & Corp. Sec.
• Dr. Geoffrey von Maltzahn Ph.D.,
  Co-Founder & Director
• Hylckama Vlieg Johan Van,
  Chief Scientific Officer
• Ventures Fund Iv General Pa...,
  
• Joshua T Brumm,
  See Remarks
• Alison Frances Lawton,
  See Remarks
• Maltzahn Geoffrey Von,
  Director
• Ventures Fund V General Par...,
  
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Alison S Long,
  Chief Medical Officer